research on retatrutide Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Retatrutide 10mg – Laboratory Research

J Pharmacol Exp Ther 369(1):129141

Its approximately six-day half-life maintains stable plasma concentrations throughout the week, so consistent adherence to a chosen day matters far more than the specific hour

Women use GLP-1s at higher rates than men, particularly those aged 5064.4 Among individuals aged 3049, women are more than twice as likely as men to have used the drugs

Phase II clinical trial results demonstrated: Body weight reduction of up to 2% at 48 weeks ( vs 2.1% placebo ) 83% of participants achieved 15% body weight loss at highest dose HbA1c reduction of up to 02% in Type 2 Diabetes participants ( vs 0% placebo ) Normalization of liver fat in 86% of participants with hepatic steatosis Reduction in systolic blood pressure averaging 6-8 mmHg These Phase II findings are preliminary

Our experts Written by With over 20 years of experience as an editor and content creator in the health and wellness space, Danielle Dorman excels at translating complex medical information into clear, actionable insights